Straits Times Index
3,377.65 +11.98 (+0.36%) S&P 500
4,076.60 +58.83 (+1.46%) Dow
34,086.04 +368.95 (+1.09%) Nasdaq
11,584.55 +190.74 (+1.67%) BTC-USD
23,096.70 +195.79 (+0.85%) CMC Crypto 200
523.31 +4.51 (+0.87%)
Iovance Biotherapeutics, Inc. (IOVA)
Pre-market:
| Previous close | 7.95 |
| Open | 8.01 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 1400 |
| Day's range | 7.90 - 8.19 |
| 52-week range | 5.42 - 18.73 |
| Volume | |
| Avg. volume | 5,094,736 |
| Market cap | 1.256B |
| Beta (5Y monthly) | 0.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.30 |
| Earnings date | 22 Feb 2023 - 27 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 23.58 |
- Zacks
Iovance (IOVA) to Buy Clinigen's Cancer Drug, Stock Up 11.6%
Iovance (IOVA) to acquire worldwide rights to an IL-2 product already approved by FDA for two cancer indications. The deal is expected to close by first-quarter 2023.
- Motley Fool
Why Iovance Biotherapeutics Stock Soared 12% Higher Today
Investors were more than cheered by a business update from cancer-focused biotech Iovance Biotherapeutics (NASDAQ: IOVA) on Monday. For Proleukin, an interleukin-2 molecule used to stimulate T-cell activity in the fight against cancer, Iovance is making an upfront payment of 166.7 million British pounds ($206.6 million). It is also on the hook for a 41.7 million pound ($51.7 million) milestone payment upon first approval of its leading pipeline therapy, advanced melanoma treatment Lifileucel, and what it described only as double-digit worldwide sales royalties derived from Proleukin.
- Zacks
Iovance (IOVA) Extends Timeline for Rolling BLA of Melanoma Drug
Post FDA's feedback on lifileucel, Iovance (IOVA) extends its timeline to complete the rolling BLA submission for lifileucel in melanoma. It expects to complete the filing in the first quarter.
